Management of acute promyelocytic leukemia.

Martin S. Tallman*, Chadi Nabhan

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

22 Scopus citations

Abstract

Acute promyelocytic leukemia (APL) has become the most potentially curable subtype of acute myeloid leukemia (AML) in adults. With current treatment strategies that incorporate all-trans retinoic acid (ATRA), long-term disease-free survival and potential cure rates of 70% to 80% can be expected. Such progress reflects what can be accomplished with insights into the molecular pathogenesis of leukemia, identification of a molecular target, and rapid accrual to a series of clinical trials. The leukemic promyelocytes from patients with APL are uniquely susceptible to a variety of novel agents in addition to ATRA, including arsenic trioxide, and in preliminary studies, gemtuzumab ozogamicin, the immunoconjugate comprised of an anti-CD33 monoclonal antibody linked to the potent cytotoxic agent calicheamicin. Incorporation of such agents into the treatment of patients with high-risk disease may be an important future direction to pursue.

Original languageEnglish (US)
Pages (from-to)381-389
Number of pages9
JournalCurrent oncology reports
Volume4
Issue number5
DOIs
StatePublished - Sep 2002

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Management of acute promyelocytic leukemia.'. Together they form a unique fingerprint.

Cite this